Commutability Assessment of Candidate External Quality Assessment Materials for Aminotransferase Activity Measurements Based on Different Approaches in China

Qichen Long, M.D.1*, Tianqi Qi, M.D.1*, Tianjiao Zhang, B.D.2, Jing Wang, M.D.2, Jie Zeng, B.D.2, Ying Yan, B.D.2, Meng Wang, M.D.3, Wei Huang, B.D.4, Haijian Zhao, M.D.2, Wenxiang Chen, Ph.D.2, Chuanbao Zhang, M.D.2

1National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology, Beijing Engineering Research Center of Laboratory Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China; 2National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology, Beijing Engineering Research Center of Laboratory Medicine, Beijing, P. R. China; 3Clinical Laboratory, Department, Beijing Hospital, National Center of Gerontology, Beijing, P. R. China; 4The Ministry of Health Key Laboratory of Geriatrics, Beijing Hospital, National Center of Gerontology, Beijing, P. R. China

Background: Using commutable external quality assessment (EQA) materials is important for monitoring successful harmonization efforts. We assessed the commutability of four human serum pool (HSP) preparations to identify candidate EQA materials for alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activity measurement.

Methods: One set each of 85 clinical samples (CSs) was collected for ALT and AST activity measurement. The 15 candidate EQA materials included four types of HSP preparations (A to D): materials A, C, and D contained human original recombinant (HOR) aminotransferases; materials B was mixed leftover samples. The CSs and 15 candidate EQA materials were analyzed using seven routine assays, and the ln-transformed results were analyzed in 21 assay pairs. Commutability was assessed using Deming regression, with a 95% prediction interval (CLSI approach) and the difference in bias with an error component model (International Federation of Clinical Chemistry and Laboratory Medicine [IFCC] approach).

Results: For ALT, all materials were commutable for 14–21 assay pairs according to the CLSI and IFCC approaches. For AST, B01-03 showed commutability for 14-21 assay pairs, and C01-03 and D01-03 showed commutability for no less than 10 assay pairs according to the two approaches. A01-06 were commutable for 9-16 assay pairs according to the CLSI approach, but for 6-9 assay pairs according to the IFCC approach.

Conclusions: Mixed leftover samples showed desirable commutability characteristics as candidate EQA materials for routine aminotransferase activity measurements. Human serum bases supplemented with HOR were commutable for most routine ALT activity measurements.

Key Words: Alanine aminotransferase, Aspartate aminotransferase, Commutability, External quality assessment materials

INTRODUCTION

Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activity tests are the most common liver chemistry tests, and are, respectively, the second and third most tested among all single items tested in clinical laboratories of 270 hospitals in China [1, 2]. Epidemiological evidence shows that elevated serum ALT and/or AST activity is not only symp-
Commutable EQA materials for ALT and AST

Long Q, et al.

External quality assessment (EQA) is used to evaluate the performance of routine assays regularly and monitor the success of harmonization efforts. The application of commutable EQA materials, with these materials behaving like clinical samples (CSs), is recommended to strengthen the reliability of the EQA as a monitoring tool and to avoid peer group evaluation [4-6]. The conventional lyophilized materials, which are most commonly employed in EQA, were sometimes found to be noncommutable with CSs [7-11].

To our knowledge, the commutabilities of different HSP preparations, along with 85 CSs, to assess their commutability for routine ALT and AST activity measurement, according to the CLSI EP30-A guidelines (CLSI approach) [12] and the IFCC recommendations (IFCC approach) [13-15].

MATERIALS AND METHODS

Sample details

Blood samples were collected between February and May 2018 from the clinical laboratories of Beijing Hospital, Beijing Chaoyang Hospital, and Beijing Tongren Hospital, China. CSs were fresh serum stored at 2-8°C within three days of blood collection. One milliliter of each collected CS was transferred into a vial, frozen at -80°C immediately, and stored within four months until use. This study was approved by the Ethics Committee of Beijing Hospital, with exemption for obtaining informed consent (approval No. 2018BJJYEC-019-01). In total, 85 CSs from 58 male and 27 female subjects aged 24–90 years were collected for ALT activity measurement (range, 16–318 U/L), and another 85 CSs from 51 male and 34 female subjects aged 18–94 years were collected for AST activity measurement (range, 18–334 U/L). Icteric, lipemic, and hemolyzed samples were excluded, and the activity range of the CSs covered those of the 15 candidate EQA materials for assessment in this study.

Candidate EQA materials

The 15 candidate EQA materials for commutability assessment were grouped into materials A-D based on the four types of frozen HSP preparations. Materials A were obtained from BIO-CRM Corp. (Jiaxing, China) [20] and comprised two lots, with each lot containing three concentrations (A01-03: lot 1 in 2017; A04-06: lot 2 in 2018). A01-06 were prepared using HSPs supplemented with human original recombinant (HOR) ALT and AST developed at BIO-CRM. Materials B (B01-03), prepared using the mixed leftover samples, contained natural concentrations of aminotransferase. In total, 93 leftover samples (from 44 male and 49 female subjects aged 18–89 years) were collected in vials daily between February and May 2018 at Beijing Hospital and frozen at -80°C. The frozen serum aliquots were grouped into three sets according to the original aminotransferase concentrations, thawed, and pooled to prepare B01-03 (about 20 U/L, 60 U/L, 250 U/L for ALT and 20 U/L, 70 U/L, 270 U/L for AST). Base materials C (C01-03) were leftover samples collected from healthy individuals under 30 years of age and stored at 2–8°C. The duration for leftover sample collection lasted for three days. Base materials D (D01-03) were sampled from frozen human plasma pools supplemented with mannitol-adenine-phos-
phate red blood cell preservation solution [21, 22] collected from blood banks. The frozen plasma pools were thawed and centrifuged at 2,205×g for 20 minutes to obtain the serum base material. Both materials C and D were supplemented with the same two HOR aminotransferases (i.e., one for ALT and one for AST) prepared at the Beijing Institute of Geriatrics through expression in *Escherichia coli* cells [23]. Materials C and D were adjusted to three concentrations, as close as possible to those for materials B. All materials were filtered through a 0.22-μm membrane filter using a Corning bottle-top vacuum filter in a sterile cabinet to minimize microbial contamination, mixed thoroughly by inverting, aliquoted at 1 mL/vial, and stored at -80°C until use within a month.

**ALT and AST activity measurement procedures and experimental design**

Detailed information on the seven P-5′-P-non-supplemented assays used is provided in Table 1. All assays are based on kinetic spectrophotometry (continuous-monitoring method) and were performed on a Hitachi 7180 analyzer (Hitachi High-Technologies Corp., Tokyo, Japan) in four runs, using the parameters’ setting and calibration recommended by the manufacturers for each assay. Materials A-D were interspersed among the CSs during evaluation. The test samples were thawed, mixed, and analyzed according to ALT and AST activity measurement procedures in triplicate in three phases (the first phase started with the first triplicate measurement of each sample, measurements in the second phase were performed in the reverse order, and the order in the third phase was the same as that in the first phase).

**Statistical analysis**

The 85 CSs covering the activity range of the candidate EQA materials were used to assess the commutability of materials for ALT and AST activity. The results from the seven assays were analyzed in 21 assay pairs. Ln-transformed concentrations were used to obtain the consistent scatter of the difference plot over the concentrations [14]. Commutability was assessed according to the two approaches mentioned above and are described in detail below. Data were analyzed using Microsoft Excel 2016 (Microsoft Corporation, Redmond, Washington, USA).

**CLSI approach based on linear regression analysis**

As recommended in the CLSI EP30-A guidelines [12], Deming regression was performed using the ln-transformed data for the CSs after identifying outliers in the difference plot and visually inspecting linearity by ordinary linear regression. The 95% prediction interval was calculated for the commutability assessment.

**IFCC approach based on difference in bias analysis**

Commutability assessment of candidate EQA materials

The outliers were excluded by inspecting the precision profile and difference plot. The mean bias between assay x and assay y for all CSs was denoted as $B_{CS}$, and the SD of all biases for the CSs was denoted as $s_{CS}$. The standard uncertainty for the CSs, $\mu(B_{CS})$, can be expressed using Eq. 1, where N is the number of CSs.

$$\mu(B_{CS}) = \frac{s_{CS}}{\sqrt{N}},$$  (1)

For the candidate EQA materials, bias was calculated as the difference between two assays and was denoted as $B_{RM}$. The associated uncertainty was calculated using Eq. 2, where $s_{x(RM)}$ and $s_{y(RM)}$ were estimated by pooling the SDs of the 15 candidate EQA materials’ k replicates.

$$\mu(B_{RM}) = \frac{s_{2x(RM)} + s_{2y(RM)}}{k},$$  (2)

**Table 1. Details of the seven routine assays for ALT and AST activity measurement**

| Assays | Manufacturer | Country/city | Reagent lot (ALT/AST) | Calibrator lot | Traceability of calibrator |
|--------|--------------|--------------|-----------------------|----------------|---------------------------|
| BioSino | BioSino Bio-Technology & Science | China/Beijing | 170771/170721 | 170,113 | IFCC primary reference procedure |
| BSBE | Beijing Strong Biotechnologies | China/Beijing | 17-0726/17-0717 | 877UE* | JSCC TS01 and ERM AD457† |
| DiaSys | DiaSys Diagnostic Systems | Germany /Holzheim | 3783/3763 | 21,658 | modified IFCC procedure without P-5′-P |
| KHB | Shanghai Kehua Bio-Engineering | China/Shanghai | 2017051R/2017061R | 18,642,601* | modified IFCC procedure without P-5′-P |
| LEADMAN | Beijing Leadman Biochemistry | China/Beijing | 611292K/611161K | 708101H | ERM AD454 and ERM AD457† |
| Maccura | Maccura Biotechnology | China/Chengdu | 617031/617021 | 717,031 | modified IFCC procedure without P-5′-P |
| Wako | Wako Pure Chemical Industries | Japan/Osaka | TP935, 936/TN182, 183 | TN225 | IFCC primary reference procedure |

*Randox and Roche calibrators are specified for BSBE and KHB, respectively; †Certified reference materials for ALT and AST.

Abbreviations: IFCC, International Federation of Clinical Chemistry and Laboratory Medicine; JSCC, Japan Society of Clinical Chemistry; P-5′-P, pyridoxal-5-phosphate.
The difference in bias, $D_{RM}$, was estimated using Eq. 3, with the expanded uncertainty $U(D_{RM})$ expressed by Eq. 4, in which a coverage factor of 1.9 was used to achieve a coverage of approximately 90%. The values of $D_{RM}$ and $U(D_{RM})$ were compared with the commutability criterion $C$, which was set at 6.7% for ALT and 5.6% for AST based on the biological variation [24].

$$D_{RM} = B_{RM} - B_{CS},$$

$$U(D_{RM}) = 1.9 \times \sqrt{\mu^2(B_{RM}) + \mu^2(B_{CS})}.$$ (3) (4)

Three commutability assessment outcomes are possible: (1) when the uncertainty interval $D_{RM} \pm U(D_{RM})$ is within $0 \pm C$, commutable; (2) when $D_{RM} \pm U(D_{RM})$ is outside $0 \pm C$, noncommutable; (3) when $D_{RM} \pm U(D_{RM})$ and $0 \pm C$ are overlapping, inconclusive.

**Estimates of the error component from the CSs**

The $s_{CS}$ mentioned above is the estimate of the observed variation in differences. According to the IFCC recommendations [14], $s_{MSSD}$, excluding the variability from a possible trend in differences, is used as an estimate of random error. In this study, the random error was separated into two components: the variation from replicate measurements ($s_{E}$) and the sample-specific effect ($s_{d}$). The $s_{E}$ was estimated as the pooled SDs for all CSs from replicates. To test the null hypothesis of no sample-specific effect, the test statistic was calculated using Eq. 6, where $F$ has an F-distribution. If $s_{d}$ existed, it was estimated as the residual variation between assays not accounting for other error components and expressed by Eq. 7.

$$F = \frac{k \cdot s_{MSSD}^2}{s_{E}^2},$$ (6)

$$s_{d} = \sqrt{s_{MSSD}^2 - \frac{s_{E}^2}{k}}.$$ (7)

**RESULTS**

**Commutability assessment using the CLSI approach**

The between-assay correlations of 21 assay pairs are detailed in Supplemental Data Table S1. The commutability results for the candidate EQA materials for the 21 assay pairs in the Deming regression analysis are summarized in Table 2 and detailed in Supplemental Data Tables S2 and S3. Representative commutability assessment plots based on Deming regression are shown in Fig. 1. For ALT activity measurement, out of 21 assay pairs, 15–21 commutable assay pairs were observed for materials A, and 16–21 commutable assay pairs were observed for materials

**Table 2. Summary of commutability assessment results for 15 candidate EQA materials**

| EQA materials | ALT Concentration (U/L) | Commutable pairs in CLSI | Commutable pairs in IFCC | AST Concentration (U/L) | Commutable pairs in CLSI | Commutable pairs in IFCC |
|---------------|-------------------------|--------------------------|--------------------------|-------------------------|--------------------------|--------------------------|
| A01           | 94.1                    | 21/21                    | 21/21                    | 34.5                    | 13/21                    | 9/21                     |
| A02           | 172.5                   | 21/21                    | 21/21                    | 43.5                    | 9/21                     | 6/21                     |
| A03           | 257.0                   | 21/21                    | 21/21                    | 62.8                    | 9/21                     | 7/21                     |
| A04           | 39.2                    | 15/21                    | 14/21                    | 31.8                    | 16/21                    | 7/21                     |
| A05           | 130.6                   | 21/21                    | 21/21                    | 95.2                    | 10/21                    | 6/21                     |
| A06           | 210.9                   | 20/21                    | 20/21                    | 191.1                   | 11/21                    | 9/21                     |
| B01           | 20.6                    | 20/21                    | 15/21                    | 20.8                    | 21/21                    | 14/21                    |
| B02           | 58.0                    | 21/21                    | 21/21                    | 66.6                    | 21/21                    | 18/21                    |
| B03           | 256.0                   | 21/21                    | 21/21                    | 272.0                   | 21/21                    | 19/21                    |
| C01           | 20.9                    | 16/21                    | 16/21                    | 25.5                    | 18/21                    | 10/21                    |
| C02           | 57.9                    | 21/21                    | 21/21                    | 61.4                    | 15/21                    | 15/21                    |
| C03           | 280.5                   | 21/21                    | 21/21                    | 279.7                   | 15/21                    | 10/21                    |
| D01           | 22.5                    | 16/21                    | 21/21                    | 20.4                    | 15/21                    | 10/21                    |
| D02           | 62.7                    | 21/21                    | 21/21                    | 55.2                    | 15/21                    | 13/21                    |
| D03           | 307.1                   | 21/21                    | 19/21                    | 265.7                   | 15/21                    | 10/21                    |

Abbreviations: CLSI, Clinical and Laboratory Standards Institute; EQA, external quality assessment; IFCC, International Federation of Clinical Chemistry and Laboratory Medicine.
B to D (Table 2). For AST activity measurement, materials A showed commutability for 9–16 out of 21 assay pairs, whereas materials B to D showed commutability for 15–21 assay pairs (Table 2).

Commutability assessment using the IFCC approach
The results of commutability assessment based on difference in bias of the In-transformed concentrations are summarized in Table 2 and detailed in the Supplemental Data Tables S4 and S5.
S5. Representative commutability assessment plots created using the difference in bias approach are shown in Fig. 1. The commutability assessment results for ALT activity demonstrated that all materials A showed commutability for 14–21 out of 21 assay pairs and materials B to D showed commutability for 15–21 assay pairs (Table 2). In the AST activity commutability assessment, materials A showed commutability for 6–9 out of 21 assay pairs, materials B for 14–19 assay pairs, and materials C and D for 10–15 assay pairs (Table 2).

Error components contributing to the differences among the 21 assay pairs are presented in Table 3. For ALT activity measurement, the values of $s_{CS}$ for the 21 assay pairs ranged from 0.011 to 0.035, whereas those of $s_r$, the variation from replicates, ranged from 0.005 to 0.009, and those of $s_d$, the sample-specific effect, ranged from 0.008 to 0.018. For AST activity measurement, the $s_{CS}$ was 0.011–0.038, $s_r$ was 0.009–0.016, and $s_d$ was 0.007–0.029 for the 21 assay pairs.

**DISCUSSION**

To propel the harmonization of aminotransferase activity measurements, the commutability of HSP preparations was assessed in this study, and two commutability assessment approaches were compared. Results of the CLSI approach for ALT activity showed no obvious difference when compared with those of the IFCC approach (Table 2; and Supplemental Data Tables S2 and S4). For AST activity, more commutability was observed for the CLSI approach than for the IFCC approach, although the overall conclusions were largely the same between the two approaches (Table 2; and Supplemental Data Tables S3 and S5). These observations suggested that the commutability criteria in these two approaches had similar stringencies for the ALT assay pairs, whereas the criterion for the AST assay pairs in the CLSI approach was less stringent than that in the IFCC approach. A possible explanation is that the criterion in the IFCC approach is fixed and based on medical requirements, whereas

**Table 3. Estimate of error components for routine assay pairs of clinical samples**

| Assay pairs (X-Y) | ALT | AST |
|------------------|-----|-----|
|                  | $s_{CS}$ | $s_r$ | $s_d$ | $P^*$ | $s_{CS}$ | $s_r$ | $s_d$ | $P^*$ |
| Biosino-BSBE     | 0.017 | 0.005 | 0.013 | <0.05 | 0.024 | 0.015 | 0.014 | <0.05 |
| Biosino-DiaSys   | 0.024 | 0.006 | 0.017 | <0.05 | 0.018 | 0.012 | 0.008 | <0.05 |
| Biosino-KHB      | 0.011 | 0.008 | 0.015 | <0.05 | 0.018 | 0.011 | 0.009 | <0.05 |
| Biosino-LEADMANN | 0.029 | 0.006 | 0.015 | <0.05 | 0.029 | 0.012 | 0.023 | <0.05 |
| Biosino-Maccura  | 0.026 | 0.006 | 0.013 | <0.05 | 0.017 | 0.013 | 0.014 | <0.05 |
| Biosino-Wako     | 0.016 | 0.006 | 0.011 | <0.05 | 0.024 | 0.015 | 0.009 | >0.05 |
| BSBE-DiaSys      | 0.021 | 0.006 | 0.015 | <0.05 | 0.017 | 0.013 | 0.011 | <0.05 |
| BSBE-KHB         | 0.014 | 0.008 | 0.012 | <0.05 | 0.020 | 0.012 | 0.010 | <0.05 |
| BSBE-LEADMANN    | 0.027 | 0.005 | 0.015 | <0.05 | 0.038 | 0.013 | 0.029 | <0.05 |
| BSBE-Maccura     | 0.026 | 0.006 | 0.015 | <0.05 | 0.011 | 0.013 | 0.008 | >0.05 |
| BSBE-Wako        | 0.015 | 0.006 | 0.010 | <0.05 | 0.027 | 0.016 | 0.015 | <0.05 |
| DiaSys-KHB       | 0.024 | 0.008 | 0.013 | <0.05 | 0.018 | 0.009 | 0.014 | <0.05 |
| DiaSys-LEADMANN  | 0.035 | 0.006 | 0.016 | <0.05 | 0.017 | 0.010 | 0.017 | <0.05 |
| DiaSys-Maccura   | 0.024 | 0.007 | 0.012 | <0.05 | 0.013 | 0.011 | 0.010 | <0.05 |
| DiaSys-Wako      | 0.014 | 0.008 | 0.009 | <0.05 | 0.023 | 0.013 | 0.008 | >0.05 |
| KHB-LEADMANN     | 0.027 | 0.009 | 0.018 | <0.05 | 0.029 | 0.009 | 0.025 | <0.05 |
| KHB-Maccura      | 0.027 | 0.008 | 0.015 | <0.05 | 0.014 | 0.009 | 0.007 | <0.05 |
| KHB-Wako         | 0.016 | 0.008 | 0.011 | <0.05 | 0.016 | 0.012 | 0.013 | <0.05 |
| LEADMANN-Maccura | 0.021 | 0.006 | 0.017 | <0.05 | 0.024 | 0.010 | 0.024 | <0.05 |
| LEADMANN-Wako    | 0.025 | 0.007 | 0.013 | <0.05 | 0.034 | 0.014 | 0.022 | <0.05 |
| Maccura-Wako     | 0.017 | 0.006 | 0.008 | <0.05 | 0.023 | 0.015 | 0.011 | <0.05 |

* $P$ in the hypothesis test for the no sample-specific effect; † Routine assay pairs, including LEADMANN.

Abbreviations: $s_{CS}$, observed variation for clinical samples; $s_d$, sample-specific effect; $s_E$, replicate measurements variation.
the CLSI criterion, which uses prediction intervals, is related to the random errors in each assay pair [14, 25, 26]. The magnitude of the random errors in this study is reflected in the following analysis based on the estimation of the error components.

Based on the error model in the IFCC approach, the possible error components that led to the differences between CS assay pairs could be estimated and analyzed. The results of error component estimation (Table 3) indicated that $\text{sd}$, the sample-specific effect, was one of the main sources of random error for both ALT and AST activity measurements. For AST, $s_{\text{r}}$, the variation from replicate measurements (0.009–0.016) also substantially contributed to the disagreement between routine assay pairs, consistent with the less stringent CLSI commutability criterion. For six assay pairs related to LEADMAN, the $s_{\text{r}}$ was 0.017–0.029 ($p<0.05$), whereas the $s_{\text{r}}$ of the other assay pairs was 0.007–0.015 (Table 3). The LEADMAN assay tended to show a larger residual standard deviation ($S_{\text{r}}$) based on a correlation analysis, in which the results of each assay and the mean of the seven assays were compared (Supplemental Data Table S6). Therefore, the LEADMAN assay could have a limitation in terms of measurement selectivity. In addition, for assay pairs related to LEADMAN, there tended to be more non-commutability in the two approaches than for other assay pairs (Supplemental Data Tables S3 and S5). A possible reason is the above-mentioned limitation in the LEADMAN assay or the non-commutability of those materials.

Collecting blood from donors and rigorously preparing fresh HSPs according to the CLSI C37-A guidelines [27] are the most effective approaches to obtain commutable materials [5, 28]. Another promising source of commutable materials is leftover samples, which are easier to obtain. Considering the complex preparation of multienzyme EQA materials and the higher concentrations of EQA materials, except those for mixed leftover samples, materials with supplementation of HOR in the human serum base were also prepared in this study. Thus, four different types of HSP preparations were analyzed to identify their commutability and select candidate EQA materials. For ALT, all materials showed desirable commutability based on the CLSI and IFCC approaches. B01-03 also showed satisfying commutability for AST (Table 2; CLSI: 21–21 out of 21, IFCC: 14–19 out of 21). These observations suggested desirable commutability of the mixed leftover samples for both ALT and AST. For other HSP preparations with HORs in AST activity measurements, A01-06 showed undesirable commutability (6-9), whereas materials C-D were commutable for 10–15 assay pairs based on the IFCC approach (Table 2). The major difference between materials A and C-D is the supplemented HORs, which are from different origins. It is difficult to determine whether the commutability of the materials C-D for AST is satisfactory, since it remains inconclusive whether measurement selectivity limitations are related to the LEADMAN assay or the materials themselves resulted in noncommutability in the current experimental design. Nevertheless, human serum base supplemented with HOR showed great potential as a commutable EQA material for ALT and AST activity measurement [29, 30]. However, the HOR source affects the commutability of candidate EQA materials for AST activity measurement and should therefore be considered.

Commutability assessment is a continuing task for institutions and EQA manufacturers. Since the commutability conclusion from one lot or one concentration cannot be applied arbitrarily to others [7-10], we investigated multiple lots and concentrations of candidate EQA materials. Considering the wide-spread use of the heterogeneous system, which accounts for 61% of all measurements (1652/2722 from EQA data in 2018) in Chinese laboratories, we used the Hitachi 7180 analyzer, with combinations of seven mainstream reagents in the current study. In the future, other systems, including, Beckman AU5800, Siemens Advia 2400, and Roche Cobas 8000, should be investigated.

The plasma processing for the base materials D might produce precipitation despite a few steps of centrifugation or filtering. However, we did not observe coagulation during the preparation and testing of these materials. Considering the stability of ALT and AST activity, it is difficult to use fresh CSs in a large-scale commutability study using seven routine assays. Therefore, CSs were frozen until analysis according to previous enzyme commutability studies and the EP30-A guidelines [12, 25, 31]. In the current study design, with three measurements in three phases, the position effect (variation from measurement order) for the IFCC approach was lost in the replicate measurements variation ($s_{\text{r}}$) due to nonadjacent replicates [25]. However, the relatively small values of $s_{\text{r}}$ for ALT indicated that position effects may not have been a major variation source for ALT.

In conclusion, mixed leftover samples showed desirable commutability characteristics as candidate EQA materials for routine aminotransferase activity measurements. Human serum bases supplemented with HOR were also commutable for most routine ALT activity measurements.

ACKNOWLEDGMENTS

The authors gratefully acknowledge their colleagues at Beijing Chaoyang Hospital Department of Laboratory Medicine and Bei-
jing Tongren Hospital Department of Laboratory Medicine for their kind assistance in providing residual clinical samples.

**AUTHOR CONTRIBUTIONS**

Z TJ and W J conceived and planned the study. Q T Q collected samples with the help of W M. H W prepared human original recombinase. Q T Q and L Q C prepared materials B-D and carried out all the measurements. Y Y and Z H J performed the data analysis. L Q C wrote the draft of the manuscript. Z J reviewed and edited the manuscript. Z C B and C W X supervised the study. All authors read and approved the final version of the manuscript.

**CONFLICTS OF INTEREST**

No potential conflicts of interest relevant to this article were reported.

**ORCID**

Qichen Long https://orcid.org/0000-0001-7545-7230  
Tianqi Qi https://orcid.org/0000-0002-9951-9229  
Tianjiao Zhang https://orcid.org/0000-0003-4328-814X  
Jing Wang https://orcid.org/0000-0002-4127-5743  
Jie Zeng https://orcid.org/0000-0002-7807-7994  
Ying Yan https://orcid.org/0000-0003-1459-2038  
Meng Wang https://orcid.org/0000-0002-0185-5903  
Wei Huang https://orcid.org/0000-0002-2936-5009  
Haijian Zhao https://orcid.org/0000-0002-7850-7827  
Wenxiang Chen https://orcid.org/0000-0001-5704-3368  
Chuanbao Zhang https://orcid.org/0000-0003-0754-7511

**RESEARCH FUNDING**

This research was supported by The National Key Research and Development Program of China (2018YFC1002204).

**REFERENCES**

1. Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol 2017;112:18-35.
2. Zhong K, Wang W, Falin H, Wang Z. Investigation and analysis of current application status of testing items of clinical laboratories in China. Chin J Lab Med 2015;38:637-41.
3. Krishnamurthy S, Korienblat KM, Scott MG. Persistent increase in aspartate aminotransferase in an asymptomatic patient. Clin Chem 2009;55:1573-5.
4. Miller WG and Myers GL. Commutability still matters. Clin Chem 2013;59:1291-3.
5. Miller WG, Jones GR, Horowitz GL, Weykamp C. Proficiency testing/external quality assessment: current challenges and future directions. Clin Chem 2011;57:1670-80.
6. Cobaert C, Weykamp C, Franck P, de Jonge R, Kuipers A, Steigstra H, et al. Systematic monitoring of standardization and harmonization status with commutable EQA-samples—Five year experience from the Netherlands. Chin Chim Acta 2012;414:234-40.
7. Zhang T, Zeng J, Wang M, Zhang C, Zhang J, Zhao H, et al. The commutability of reference materials for serum glucose measurements. Chin J Lab Med 2015;38:296-300.
8. Zhang S, Zeng J, Zhang C, Li Y, Zhao H, Cheng F, et al. Commutability of possible external quality assessment materials for cardiac troponin measurement. PLoS One 2014;9:e102046.
9. Ge M, Zhao H, Yan Y, Zhang T, Zeng J, Wang Y, et al. Evaluation of the bias of serum magnesium measurements and the commutability of processed materials. Clin Lab 2016;62:921-30.
10. Meng Q, Zhou W, Zhang C, Zeng J, Zhao H, Zhang T, et al. Serum triglyceride measurements: the commutability of reference materials and the accuracy of results. Clin Chem Lab Med 2017;55:1284-90.
11. Zeng J, Qi T, Wang S, Zhang T, Zhou W, Zhao H, et al. Commutability of control materials for external quality assessment of serum apolipoprotein A-I measurement. Clin Chem Lab Med 2018;56:789-95.
12. CLSI. Characterization and qualification of commutable reference materials for laboratory medicine; approved guideline. EP30-A Wayne, PA: Clinical and Laboratory Standards Institute. 2010.
13. Miller WG, Schimmel H, Rej R, Greenberg N, Ceriotti F, Bums C, et al. IFCC Working Group Recommendations for Assessing Commutability Part 1: General experimental design. Clin Chem 2018;64:447-54.
14. Nilsson G, Budd JR, Greenberg N, Delatorre V, Rej R, Panteghini M, et al. IFCC Working Group Recommendations for Assessing Commutability Part 2: Using the difference in bias between a reference material and clinical samples. Clin Chem 2018;64:455-64.
15. Budd JR, Weykamp C, Rej R, MacKenzie F, Ceriotti F, Greenberg N, et al. IFCC Working Group Recommendations for Assessing Commutability Part 3: Using the calibration effectiveness of a reference material. Clin Chem 2018;64:465-74.
16. Schumann G, Bonora F, Ceriotti F, Férard G, Ferrero CA, Franck PF, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 4. Reference procedure for the measurement of catalytic concentration of alanine aminotransferase. Clin Chem Lab Med 2002;40:718-24.
17. Schumann G, Bonora F, Ceriotti F, Férard G, Ferrero CA, Franck PF, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 5. Reference procedure for the measurement of catalytic concentration of aspartate aminotransferase. Clin Chem Lab Med 2002;40:725-33.
18. Westerhuis LW and Hafkenscheid JC. Apoenzyme content of serum aminotransferases in relation to plasma pyridoxal-5'-phosphate concentration. Clin Chem 1983;29:789-92.
19. National Center for Clinical Laboratories. https://www.nccl.org.cn/ (Updated on Nov 2019).
20. Bio CRM. Product center/customized service. https://www.biotech-crm.com/ (Updated on Nov 2019).
21. Nishino T, Yachie-Kinoshita A, Hirayama A, Soga T, Suematsu M, Tomita M. In silico modeling and metabolome analysis of long-stored erythrocytes to improve blood storage methods. J Biotechnol 2009;144:212-
23. Yang P, Zhou J, Kang Y, Gong L, Zhang J, Yu J, et al. Mannitol-adenine-phosphate: a novel solution for intraoperative blood salvage. Transfusion 2014;54:1146-52.
24. Carobene A, Røraas T, Selvik UØ, Sylte MS, Sandberg S, Guerra E, et al. Biological variation estimates obtained from 91 healthy study participants for 9 enzymes in serum. Clin Chem 2017;63:1141-50.
25. Deprez L, Toussaint B, Zegers I, Schimmel H, Grote-Koska D, Klauke R, et al. Commutability assessment of candidate reference materials for pancreatic alpha-amylase. Clin Chem 2018;64:1193-202.
26. Korzun WJ, Nilsson G, Bachmann LM, Myers GL, Sakurabayashi I, Nakajima K, et al. Difference in bias approach for commutability assessment: application to frozen pools of human serum measured by 8 direct methods for HDL and LDL cholesterol. Clin Chem 2015;61:1107-13.
27. CLSI. Preparation and validation of commutable frozen human serum pools as secondary reference materials for cholesterol measurement procedures; approved guideline. C37-A Wayne, PA: Clinical and Laboratory Standards Institute. 1999.
### Supplemental Data Table S1. Between-assay correlations of 21 assay pairs for clinical samples based on Deming regression

| Assay pairs (X-Y) | ALT Outliers | r² | DR slope (95% CI) | DR intercept (95% CI) | AST Outliers | r² | DR slope (95% CI) | DR intercept (95% CI) |
|-------------------|--------------|----|-------------------|-----------------------|--------------|----|-------------------|-----------------------|
| Biosino-BSBE      | 1/85         | 0.9994 | 1.00 (0.99-1.00) | 0.05 (0.04 to 0.07) | 1/85         | 0.9987 | 0.99 (0.99-1.00) | -0.03 (-0.05 to 0.00) |
| Biosino-Diasys    | 1/85         | 0.9989 | 0.98 (0.97-0.98) | 0.08 (0.05 to 0.10) | 3/85         | 0.9992 | 1.00 (0.99-1.00) | 0.03 (0.01 to 0.05)  |
| Biosino-KHB       | 0/85         | 0.9990 | 1.00 (1.00-1.01) | -0.11 (-0.13 to -0.09) | 3/85         | 0.9994 | 1.00 (1.00-1.01) | -0.07 (-0.09 to -0.06) |
| Biosino-LEADMAN   | 2/85         | 0.9986 | 0.98 (0.98-0.99) | 0.02 (0.00 to 0.05)  | 2/85         | 0.9978 | 0.99 (0.98-1.00) | 0.10 (0.07 to 0.13)  |
| Biosino-Maccura   | 0/85         | 0.9958 | 0.99 (0.98-0.99) | 0.03 (-0.01 to 0.07) | 1/85         | 0.9990 | 1.00 (0.99-1.00) | 0.01 (-0.01 to 0.03) |
| Biosino-Wako      | 1/85         | 0.9991 | 0.98 (0.98-0.98) | 0.06 (0.04 to 0.08)  | 2/85         | 0.9988 | 1.01 (1.01-1.02) | -0.09 (-0.11 to -0.06) |
| BSBE-Diasys       | 0/85         | 0.9991 | 0.98 (0.98-0.98) | 0.03 (0.01 to 0.05)  | 1/85         | 0.9988 | 1.01 (1.00-1.01) | 0.04 (0.02 to 0.07)  |
| BSBE-KHB          | 2/85         | 0.9993 | 1.01 (1.00-1.01) | -0.15 (-0.17 to -0.14) | 2/85         | 0.9991 | 1.01 (1.01-1.02) | -0.05 (-0.07 to -0.03) |
| BSBE-LEADMAN      | 3/85         | 0.9990 | 0.99 (0.98-0.99) | -0.03 (-0.05 to -0.01) | 0/85         | 0.9967 | 1.00 (0.99-1.01) | 0.13 (0.09 to 0.16)  |
| BSBE-Maccura      | 0/85         | 0.9984 | 0.98 (0.97-0.98) | 0.07 (0.04 to 0.09)  | 0/85         | 0.9992 | 1.00 (1.00-1.01) | 0.04 (0.02 to 0.05)  |
| BSBE-Wako         | 1/85         | 0.9993 | 0.98 (0.98-0.99) | 0.01 (-0.01 to 0.03) | 1/85         | 0.9985 | 1.02 (1.02-1.03) | -0.06 (-0.09 to -0.04) |
| DiaSys-KHB        | 2/85         | 0.9990 | 1.03 (1.02-1.03) | -0.18 (-0.21 to -0.16) | 2/85         | 0.9993 | 1.01 (1.00-1.01) | -0.11 (-0.12 to -0.09) |
| DiaSys-LEADMAN    | 3/85         | 0.9989 | 1.01 (1.00-1.01) | -0.06 (-0.08 to -0.03) | 1/85         | 0.9987 | 1.00 (0.99-1.00) | 0.07 (0.05 to 0.10)  |
| DiaSys-Maccura    | 1/85         | 0.9990 | 0.99 (0.99-1.00) | 0.05 (0.03 to 0.07)  | 1/85         | 0.9991 | 1.00 (0.99-1.00) | -0.01 (-0.03 to 0.01) |
| DiaSys-Wako       | 0/85         | 0.9995 | 1.00 (1.00-1.01) | -0.02 (-0.03 to 0.00) | 2/85         | 0.9993 | 1.02 (1.01-1.02) | -0.11 (-0.13 to -0.09) |
| KHB-LEADMAN       | 2/85         | 0.9985 | 0.98 (0.97-0.99) | 0.13 (0.10 to 0.15)  | 2/85         | 0.9978 | 0.99 (0.98-1.00) | 0.17 (0.14 to 0.20)  |
| KHB-Maccura       | 1/85         | 0.9980 | 0.97 (0.96-0.98) | 0.21 (0.19 to 0.24)  | 2/85         | 0.9995 | 0.99 (0.99-1.00) | 0.09 (0.07 to 0.10)  |
| KHB-Wako          | 2/85         | 0.9989 | 0.98 (0.97-0.98) | 0.16 (0.14 to 0.19)  | 2/85         | 0.9991 | 1.01 (1.01-1.01) | -0.01 (-0.02 to 0.01) |
| LEADMAN-Maccura   | 2/85         | 0.9985 | 0.99 (0.98-0.99) | 0.11 (0.08 to 0.13)  | 1/85         | 0.9973 | 1.00 (0.99-1.01) | -0.08 (-0.12 to -0.05) |
| LEADMAN-Wako      | 3/85         | 0.9992 | 1.00 (0.99-1.00) | 0.05 (0.03 to 0.07)  | 1/85         | 0.9981 | 1.02 (1.02-1.03) | -0.18 (-0.21 to -0.15) |
| Maccura-Wako      | 1/85         | 0.9994 | 1.01 (1.00-1.01) | -0.05 (-0.06 to -0.03) | 0/85         | 0.9989 | 1.02 (1.01-1.02) | -0.10 (-0.12 to -0.08) |

Abbreviations: DR, Deming regression; r², determination of coefficient; CI, confidence interval.
### Supplemental Data Table S2. Commutability for ALT activity measurements in candidate EQA materials according to the CLSI approach

| Assay pairs (X-Y) | A01 | A02 | A03 | A04 | A05 | A06 | B01 | B02 | B03 | C01 | C02 | C03 | D01 | D02 | D03 |
|-------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Biosino-BSBE      | C   | C   | C   | C   | C   | C   | C   | C   | C   | NC  | C   | C   | C   | C   | C   |
| Biosino-DiaSys    | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | NC  | C   | C   | C   | C   |
| Biosino-KHB       | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| Biosino-LEADMAN   | C   | C   | C   | NC  | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| Biosino-Maccura   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| Biosino-Wako      | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| BSBE-DiaSys       | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | NC  | C   | C   | C   | C   |
| BSBE-KHB          | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| BSBE-LEADMAN      | C   | C   | C   | NC  | C   | C   | C   | C   | C   | C   | NC  | C   | C   | C   | C   |
| BSBE-Maccura      | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | NC  | C   | C   | C   | C   |
| BSBE-Wako         | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| DiaSys-KHB        | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | NC  | C   | C   |
| DiaSys-LEADMAN    | C   | C   | C   | NC  | C   | C   | C   | C   | C   | C   | C   | C   | NC  | C   | C   |
| DiaSys-Maccura    | C   | C   | C   | NC  | C   | C   | C   | C   | C   | C   | NC  | C   | C   | C   | C   |
| DiaSys-Wako       | C   | C   | C   | NC  | C   | C   | C   | C   | C   | C   | NC  | C   | C   | C   | C   |
| KHB-LEADMAN       | C   | C   | C   | NC  | C   | NC  | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| KHB-Maccura       | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| KHB-Wako          | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| LEADMAN-Maccura   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| LEADMAN-Wako      | C   | C   | C   | NC  | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| Maccura-Wako      | C   | C   | C   | C   | C   | C   | NC  | C   | C   | NC  | C   | C   | C   | C   | C   |

Abbreviations: C, commutable; NC, noncommutable; EQA, external quality assessment.
### Supplemental Data Table S3. Commutability for AST activity measurements in candidate EQA materials according to the CLSI approach

| Assay pairs (X-Y)                  | A01 | A02 | A03 | A04 | A05 | A06 | B01 | B02 | B03 | C01 | C02 | C03 | D01 | D02 | D03 |
|-----------------------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Biosino-BSBE                      | C   | C   | C   | C   | NC  | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| Biosino-DiaSys                    | C   | C   | NC  | NC  | NC  | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| Biosino-KHB                       | C   | NC  | NC  | C   | NC  | NC  | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| Biosino-LEADMAN*                  | NC  | NC  | NC  | C   | C   | C   | C   | C   | C   | NC  | NC  | NC  | NC  | NC  | NC  |
| Biosino-Maccura                   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| Biosino-Wako                      | C   | C   | C   | C   | NC  | NC  | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| BSBE-DiaSys                       | NC  | NC  | NC  | C   | C   | C   | C   | C   | C   | C   | C   | C   | NC  | C   | C   |
| BSBE-KHB                          | C   | C   | C   | C   | NC  | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| BSBE-LEADMAN*                     | NC  | NC  | NC  | C   | NC  | C   | C   | C   | C   | NC  | NC  | NC  | NC  | NC  | NC  |
| BSBE-Maccura                      | C   | C   | C   | C   | NC  | C   | C   | C   | C   | C   | C   | C   | NC  | C   | C   |
| BSBE-Wako                         | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| DiaSys-KHB                        | NC  | NC  | NC  | C   | C   | NC  | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| DiaSys-LEADMAN*                   | C   | NC  | NC  | C   | NC  | NC  | C   | C   | C   | NC  | NC  | NC  | C   | NC  | NC  |
| DiaSys-Maccura                    | C   | NC  | NC  | NC  | NC  | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| DiaSys-Wako                       | NC  | NC  | NC  | C   | C   | NC  | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| KHB-LEADMAN*                      | NC  | NC  | NC  | C   | NC  | C   | C   | C   | C   | NC  | NC  | NC  | NC  | NC  | NC  |
| KHB-Maccura                       | C   | NC  | C   | NC  | NC  | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| KHB-Wako                          | C   | C   | C   | C   | NC  | NC  | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| LEADMAN-Maccura                   | NC  | NC  | NC  | NC  | C   | NC  | C   | C   | C   | NC  | NC  | C   | NC  | NC  | NC  |
| LEADMAN-Wako*                     | NC  | NC  | NC  | C   | NC  | NC  | C   | C   | NC  | NC  | NC  | NC  | NC  | NC  | NC  |
| Maccura-Wako                      | C   | C   | C   | NC  | NC  | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |

*Routine assay pairs, including LEADMAN.
Abbreviations: C, commutable; NC, noncommutable; EQA, external quality assessment.
Supplemental Data Table S4. Commutability for ALT activity measurements in candidate EQA materials according to the IFCC approach

| Assay pairs (X-Y) | A01 | A02 | A03 | A04 | A05 | A06 | B01 | B02 | B03 | C01 | C02 | C03 | D01 | D02 | D03 |
|------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Biosino-BSBE     | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| Biosino-DiaSys   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| Biosino-KHB      | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| Biosino-Maccura  | C   | C   | I   | C   | C   | I   | C   | C   | I   | C   | C   | C   | C   | C   | C   |
| Biosino-Wako     | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| BSBE-DiaSys      | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| BSBE-KHB         | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| BSBE-Maccura     | C   | C   | I   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| DiaSys-KHB       | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| DiaSys-Maccura   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| DiaSys-Wako      | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| KHB-LEADMAN      | C   | C   | I   | C   | I   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| KHB-Maccura      | C   | C   | I   | C   | C   | I   | C   | C   | I   | C   | C   | C   | C   | C   | C   |
| KHB-Wako         | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| LEADMAN-Maccura  | C   | C   | C   | C   | C   | I   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| LEADMAN-Wako     | C   | C   | C   | I   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| Maccura-Wako     | C   | C   | C   | C   | C   | I   | C   | C   | I   | C   | C   | C   | C   | C   | C   |

Abbreviations: C, commutable; NC, noncommutable; I, inconclusive; EQA, external quality assessment.
### Supplemental Data Table S5. Commutability for AST activity measurements in candidate EQA materials according to the IFCC approach

| Assay pairs (X-Y) | A01 | A02 | A03 | A04 | A05 | A06 | B01 | B02 | B03 | C01 | C02 | C03 | D01 | D02 | D03 |
|------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Biosino-BSBE     | C   | I   | C   | C   | NC  | C   | I   | C   | C   | C   | C   | I   | C   | I   | I   |
| Biosino-DiaSys   | C   | C   | I   | I   | NC  | C   | C   | C   | C   | C   | C   | C   | I   | C   | C   |
| Biosino-KHB      | I   | I   | I   | I   | I   | I   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| Biosino-LEADMAN* | NC  | NC  | NC  | I   | C   | I   | C   | I   | C   | I   | NC  | NC  | NC  | I   | NC  |
| Biosino-Maccura  | C   | C   | C   | I   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| Biosino-Wako     | I   | I   | I   | I   | NC  | I   | C   | I   | C   | I   | C   | C   | C   | C   | C   |
| BSBE-DiaSys      | I   | I   | I   | I   | C   | I   | C   | C   | C   | C   | C   | C   | I   | C   | C   |
| BSBE-KHB         | C   | C   | C   | I   | I   | I   | I   | I   | C   | C   | C   | I   | C   | C   | I   |
| BSBE-LEADMAN*    | NC  | NC  | NC  | I   | NC  | I   | I   | I   | C   | I   | NC  | NC  | NC  | NC  | NC  |
| BSBE-Maccura     | C   | C   | C   | I   | NC  | C   | I   | C   | C   | C   | C   | C   | I   | C   | C   |
| BSBE-Wako        | C   | C   | C   | I   | I   | C   | I   | I   | C   | I   | C   | I   | C   | I   | I   |
| DiaSys-KHB       | I   | NC  | NC  | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| DiaSys-LEADMAN*  | I   | I   | NC  | C   | I   | NC  | C   | C   | C   | C   | I   | I   | NC  | I   | NC  |
| DiaSys-Maccura   | C   | I   | I   | NC  | NC  | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| DiaSys-Wako      | I   | I   | I   | NC  | NC  | C   | C   | C   | C   | C   | C   | C   | C   | I   | C   |
| KHB-LEADMAN*     | NC  | NC  | NC  | C   | I   | NC  | C   | C   | C   | I   | NC  | NC  | NC  | NC  | NC  |
| KHB-Maccura      | C   | I   | C   | NC  | NC  | C   | C   | C   | C   | C   | C   | C   | C   | C   | C   |
| KHB-Wako         | C   | C   | I   | C   | I   | C   | C   | I   | C   | C   | C   | C   | C   | C   | C   |
| LEADMAN-Maccura* | NC  | NC  | NC  | NC  | C   | NC  | C   | C   | C   | I   | NC  | NC  | I   | NC  | NC  |
| LEADMAN-Wako*    | NC  | NC  | NC  | C   | NC  | NC  | C   | C   | C   | NC  | NC  | I   | NC  | I   | I   |
| Maccura-Wako     | I   | I   | C   | NC  | NC  | I   | C   | C   | I   | I   | C   | I   | I   | C   | I   |

*Routine assay pairs, including LEADMAN.

Abbreviations: C, commutable; NC, noncommutable; I, inconclusive; EQA, external quality assessment.
**Supplemental Data Table S6.** Correlation analysis between seven routine assays and the means of all assays for 85 clinical samples

| Assay   | $r^2$  | Slope (95% CI) | Intercept (95% CI) | $S_{yx}$ | $r^2$  | Slope (95% CI) | Intercept (95% CI) | $S_{yx}$ |
|---------|--------|----------------|-------------------|----------|--------|----------------|-------------------|----------|
| Biosino | 0.9999 | 1.04 (1.04-1.05) | -0.88 (-1.11 to -0.66) | 0.63     | 0.9999 | 1.02 (1.02-1.02) | -0.30 (-0.52 to -0.08) | 0.69     |
| BSBE    | 0.9999 | 1.07 (1.07-1.08) | -0.58 (-0.87 to -0.28) | 0.83     | 0.9998 | 0.94 (0.94-0.95) | 0.40 (0.06 to 0.74) | 1.06     |
| Diasys  | 0.9999 | 0.98 (0.98-0.98) | 1.01 (0.76 to 1.26)   | 0.71     | 0.9999 | 1.02 (1.01-1.02) | 0.39 (0.14 to 0.63) | 0.76     |
| KHB     | 0.9999 | 0.95 (0.94-0.95) | -0.95 (-1.22 to -0.69) | 0.75     | 1.0000 | 0.96 (0.96-0.96) | -0.34 (-0.51 to -0.17) | 0.52     |
| LEADMAN*| 0.9998 | 0.96 (0.96-0.97) | 0.14 (-0.22 to 0.50)  | 1.02     | 0.9997 | 1.06 (1.06-1.07) | 0.75 (0.26 to 1.24)  | 1.51     |
| Maccura | 0.9998 | 1.00 (1.00-1.00) | 0.80 (0.43 to 1.17)   | 1.04     | 0.9999 | 1.00 (1.00-1.01) | 0.09 (-0.21 to 0.40) | 0.93     |

*LEADMAN routine assay.

Abbreviations: $r^2$, determination of coefficient; CI, confidence interval; $S_{yx}$, residual standard deviation.